Diaxonhit announces the good performance of BJI InoPlex(r)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Diaxonhit announces the good performance of BJI InoPlex(r) its test for the diagnosis of prosthetic infections at the 34th RICAI meeting
  • The first non-invasive, quick and objective test for identification of antibacterial antibodies from a simple blood sample
  • A test targeting different families of bacteria, particularly staphylococci, most responsible for prosthetic joint infections and a major public health issue
  • A diagnosis contributing to early detection of prosthetic infections and optimization of patients care by orthopedic surgeons and infectiologists

Paris, France, Dec. 1, 2014 (GLOBE NEWSWIRE) --  DIAXONHIT (Alternext : ALEHT, FR0004054427), a French leader in specialty in-vitro diagnostics for transplantation, infectious diseases and cancer, announces the good performance of BJI InoPlex®, the first blood test for the diagnosis of prosthetic joint infections at a symposium held during the 34 th RICAI meeting in Paris, France.

This performance was derived from BJI InoPlex® clinical validation study conducted in two French reference centers for prosthetic joint infections. A large cohort of 455 patients was recruited for this study.

Prosthetic joint infections, a major public health issue Each year, nearly 3 million implants are placed in Europe and the United States, including more than 220,000 hip and knee replacements in France.

About 10 to 20% of all patients undergoing replacements may experience pain or functional impairment, even long after implant surgery. Identifying whether the cause of such dysfunction is infectious or mechanical becomes necessary. If the diagnosis of prosthetic infections in the weeks or first few months following surgery is usually not a problem because clinical signs are visible, it becomes more difficult with time, thus delaying relevant care of the patient. Infections may indeed become serious complications depending on the pathogenicity of the identified bacterium and the duration of the infection.

As a result, a faster detection of prosthetic infection is capital. This is particularly the case for infections by staphilococci, the most often identified bacteria and among the most aggressive.

" Staphylococci are the most frequently observed bacteria in prosthetic joint infections and represent more than half of such infections. Staphylococci infections can be particularly severe especially in the case of Staphylococcus aureus, and difficult to diagnose when dealing with skin staphylococci. It is therefore interesting to have an easy-to-use serum test that can help assert the existence of an infection and guide the microbiological diagnosis. " said Professor Eric Senneville, Head of Infectious and Tropical Diseases and Infectiologist in the Tourcoing hospital.

A new test that, together with the standard assessments, allows practitioners to provide earlier and more tailored patient care
Currently, diagnostic tools available to diagnose prosthetic infections have limited performances, resulting sometimes in unsuitable patient care and late diagnosis.

BJI InoPlex® is the first test able to detect, directly in the patient's blood, antibodies against bacteria types frequently responsible for prostetic infections, including staphylococci that are the most often encountered bacteria in such infections.

With this test, the result of which is made available in a few hours, whereas conventional bacteriological culture requires from several days to over a week, the practitioner receives quick qualitative information by targeted types of bacteria, which enables him, in association with conventional assessments, to accelerate initiation of relevant patient care, particularly in terms of antibiotic therapy.

BJI InoPlex® only requires a single patient blood sample. After proper preparation, the test is carried out directly in the biology laboratory of the hospital with a standard Luminex instrument. It provides a quick result to the prescriber who is then able to offer a more personalized support to the patient.

According to Dr. Thomas Bauer, Orthopaedic Surgeon at the Ambroise Paré Hospital in Paris and study investigator: " Today, the diagnosis of prosthetic infection is difficult because it is based on a combination of clinical, radiological and biological assessments. Despite progress in recent years, the best conventional tests taken individually display limited performance. The clinical exam can remain somewhat evocative, laboratory tests, including ESR and CRP, lack specificity, and often the radiographic signals prove to be too late. BJI InoPlex® is a noninvasive test that complement existing tools by characterizing the presence of antibodies directed against carefully selected bacterial antigens. It allows to determine, on a simple blood sample, specific biologic responses to the most frequently encountered bacterial types in orthopedic implant infections. "

" The good performance achieved in this validation study reinforces our confidence in the qualities of BJI InoPlex®, our test that addresses a significant unmet medical need, particularly in the fight against infections by staphylococci which represent a major public health problem. These results represent another important move towards the commercialization of BJI InoPlex® for which the next step is the CE mark by the end of 2014. " concludes Dr. Loïc Maurel, President of the Management Board of Diaxonhit.

Detailed results of BJI InoPlex® clinical validation study
BJI InoPlex® clinical validation study was conducted prospectively in two French reference centers for bone and joint infections (CRIOA) and focused on a large cohort of 455 patients for whom prosthetic reintervention was planned, with or without suspicion of an infection. The average age of patients was 71 years. The location of prostheses was respectively 66% at the hip, 30% at the knee and 4% at the shoulder. The prostheses were implanted on average 7.5 years before surgical reintervention. Cases of proven prosthetic infections were observed in one third of recruited patients.

As expected, staphylococci were the bacterial type most frequently represented in confirmed cases of infection with a respective frequency of 30% for S. aureus, 26% for S. epidermidis, and 6% for S. lugdunensis. BJI InoPlex® assay performances compared to microbiological results on intraoperative samples cultures are respectively 82.2% for specificity and 75.9% for sensitivity, all types of targeted staphylococci included.

Other bacteria (B-Streptococcus and Propionibacterium acnes) targeted by BJI InoPlex® are less frequent in the prevalence of prosthetic infections, and the incidence of proven intraoperative infections with these bacteria also ended up being limited in the study cohort. The high specificity of the test for these two families of bacteria preferentially orients towards the absence of an immune response against these types of bacteria, BJI InoPlex® being used in addition to other tests performed.

BJI InoPlex® development

The first phase of BJI InoPlex® development was to engineer the test by selecting the bacterial types most involved in prosthetic joint infections, and identifying antigens characterizing these types. This identification work was based on a differential approach between sera from patients with a confirmed prosthetic infection and sera from clinically healthy control patients. The selected antigens were those recognized by antibodies present in the blood of patients whose prosthesis was infected, and unrecognized in the blood of healthy patients. As a result, BJI InoPlex® identifies, in the blood of patients, antibodies targeting several antigens characterizing three bacterial types: staphylococcus, streptococcus group B, and Propionibacterium acnes.

The second phase of the development was undertaken to validate the performance of the test with an independent cohort of patients in a specific clinical trial.

About the BJI InoPlex® diagnostic test

BJI InoPlex® is a multiplex assay based on the detection, in the serum of patients wearing an osteoarticular prosthesis, of antibodies directed against key bacterial antigens recognized by the immune system during prosthetic infections. Developed with the Luminex technology using highly specific recombinant antigens, this test allows individual and simultaneous characterization of antibodies directed against three types or species of bacteria covering the majority of prosthetic infections. BJI InoPlex® notably allows the identification of serum antibodies directed against staphylococci, most often responsible for prosthetic joint infections. This test requires a very small amount of serum (10 µl) taken by a simple blood draw and can be easily repeated. BJI InoPlex® is protected by several patents covering the selected antigens and the algorithm for interpretation of results.

About DIAXONHIT

Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in in vitro diagnostics, involved from research to commercialization of specialty diagnostic products in the fields of transplantation, infectious diseases and cancer. With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, in-vitro diagnostic kits and advanced equipment, quality control products and rapid tests, including Tetanus Quick Stick ®, a proprietary product. InGen is the leading supplier in France of HLA tests manufactured by Thermo-Fisher/One Lambda, of which it is the largest commercial partner worldwide. The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering its three main specialty areas: transplantation, immuno-infection and cancer. Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of both the NYSE Alternext OSEO Innovation and the Next Biotech indices. For more information, please visit: http://www.diaxonhit.com

Symbol : ALEHT - ISIN Code: FR0004054427 - Reuters : ALEHT.PA  - Bloomberg : ALEHT:FP

Contacts

DIAXONHIT Hervé Duchesne de Lamotte, CFO, +33 (0)1 53 94 52 49, herve.delamotte@diaxonhit.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 104

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Commodity Rout Tests a Market Already Short on Nerve

Updated Category News Views 56

Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...

Continue Reading
CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 160

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 63

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 111

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 102

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Common Tiger Bets $499 on Better Outdoor Seating Design

Updated Category News Views 59

A chair that refuses to slump into the camping aisle is Common Tiger's whole argument, and frankly it is a smarter argument than another flimsy fold-up contraption pretending comfort is optional. The Los Angeles, female-founded and women-owned brand is launching with one product, The Daymaker, after four years of development. That is a long runway for a debut chair, which...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 142

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 50

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading

Top 5 Most Recently Viewed Articles

Great American Media to Broadcast 2025 National Christmas Tree Lighting

Updated Category News Views 281

Great American Media to Broadcast 2025 National Christmas Tree Lighting Great American Media is proud to announce that it will serve as the exclusive broadcast home of the 2025 National Christmas Tree Lighting, a cherished event that creates a beautiful sense of community across the nation. This unique celebration, themed "Christmas as It's Meant to Be," is an opportunity...

Continue Reading
Lucent Health Data Breach: Critical Steps for Affected Individuals

Updated Category News Views 241

Overview of the Lucent Health Data Breach In the wake of a significant data breach, many individuals are left uncertain about the status of their personal information. Lucent Health Solutions, a provider in the healthcare industry, faced a considerable security incident that compromised sensitive data, affecting numerous individuals. It is essential to understand the...

Continue Reading
BofA's Optimistic Forecast for Uber Stock Sets New Target

Updated Category News Views 186

BofA's Optimistic Forecast for Uber Stock Sets New Target BofA Securities has recently provided a positive outlook for Uber Inc. (NYSE: UBER), increasing its price target for the company’s stock from $88 to $96. With a Buy rating in place, analysts highlight the upcoming earnings report slated for release on October 31, anticipating results that could slightly exceed...

Continue Reading
Endries International Welcomes New CEO Dan Crociata

Updated Category News Views 420

Endries International Welcomes New CEO Dan Crociata Endries International Inc., a renowned name in the fastener and supply chain solutions industry, has made a significant transition in its leadership. Dan Crociata, who has played a vital role within the company as Chief Financial Officer, has been appointed the Chief Executive Officer. This change marks a new chapter in...

Continue Reading
CIWA's New Internship Initiative: Building Insurance Leaders

Updated Category News Views 142

CIWA Launches Internship Program The California Insurance Wholesalers Association (CIWA) has unveiled an exciting new initiative aimed at cultivating the next generation of insurance professionals. This Internship Program is crafted to provide college students with hands-on experience in the dynamic world of excess and surplus lines insurance. Purpose of the Internship...

Continue Reading